
(E)-Akt inhibitor-IV
CAS No. 959841-49-7
(E)-Akt inhibitor-IV( (E)-Akt inhibitor-IV? | CS-1992 | (E)-AKTIV )
Catalog No. M28654 CAS No. 959841-49-7
(E)-Akt inhibitor-IV? ((E)-AKTIV) is an inhibitor of PI3K-Akt.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 73 | Get Quote |
![]() ![]() |
5MG | 122 | Get Quote |
![]() ![]() |
10MG | 205 | Get Quote |
![]() ![]() |
25MG | 374 | Get Quote |
![]() ![]() |
50MG | 510 | Get Quote |
![]() ![]() |
100MG | 736 | Get Quote |
![]() ![]() |
200MG | 1017 | Get Quote |
![]() ![]() |
500MG | 1512 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product Name(E)-Akt inhibitor-IV
-
NoteResearch use only, not for human use.
-
Brief Description(E)-Akt inhibitor-IV? ((E)-AKTIV) is an inhibitor of PI3K-Akt.
-
Description(E)-Akt inhibitor-IV? ((E)-AKTIV) is an inhibitor of PI3K-Akt.(In Vitro):(E)-Akt inhibitor-IV shows little effects on the growth of 184B5 non-cancer cells at the average GI20?doses.
-
In Vitro——
-
In Vivo——
-
Synonyms(E)-Akt inhibitor-IV? | CS-1992 | (E)-AKTIV
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetAkt
-
RecptormAChR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number959841-49-7
-
Formula Weight616.56
-
Molecular FormulaC31H29IN4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (81.36 mM)
-
SMILESCCN(C1/C=C/N(C)c2ccccc2)c(cc(cc2)-c3nc(cccc4)c4s3)c2N1c1ccccc1.I
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tran JA, et al. Differential coupling of muscarinic M1, M2, and M3 receptors to phosphoinositide hydrolysis in urinary bladder and longitudinal muscle of the ileum of the mouse. J Pharmacol Exp Ther. 2006 Aug;318(2):649-56. Epub 2006 May 4.
molnova catalog



related products
-
Chromeceptin
Chromeceptin is an inhibitor of the IGF signaling pathway, decreases the numbers of tumorsphere, and inhibits the AKT/mTOR pathway.
-
Actein
Actein has a stimulatory effect on osteoblastic bone formation or has potential activity against osteoporosis, it also can prevent oxidative damage to osteoblasts in osteoporotic patients.
-
AT7867
AT7867 is a potent, ATP-competitive, orally available dual Akt and p70S6K inhibitor with Ki of 17-85 nM, also inhibits PKA with Ki of 20 nM.